Dr. David Jacob Andorsky, MD

Dr. Andorsky practices at Rocky Mountain Cancer Centers in Boulder, Colorado.

Dr. Andorsky's NPI, 1609061837, was assigned on September 11, 2007. Dr. Andorsky graduated from Harvard Medical School in 2002. Dr. Andorsky holds Colorado license 48556.

Dr. Andorsky's primary practice is Rocky Mountain Cancer Centers, at 4715 Arapahoe Ave, Boulder, CO 80303 in Boulder County. The practice phone is (303) 930-7800.

Dr. Andorsky's primary practice is Rocky Mountain Cancer Centers in Boulder, Colorado. Dr. Andorsky is also affiliated with Foothills Hospital. The medical group on file is Rocky Mountain Cancer Centers. Dmand AI also links Dr. Andorsky to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Andorsky practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Andorsky's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Andorsky's licenses on file in 2 states: Colorado and California.

CMS data shows 48,214 Medicare services from Dr. Andorsky across 36 procedure codes in 2024, for 607 Medicare patients. Medicare paid $1,574,484 for them. Every service was in an office.

CMS counts 607 Medicare patients who saw Dr. Andorsky in 2024. The largest group is 65 to 74, with 277 patients. 58% of them have high cholesterol, and 53% have high blood pressure. 5% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Andorsky's median patient age at 73, with 55% women.

In 2024, Dr. Andorsky wrote 1,530 Medicare Part D claims for 236 patients. 63% of them were for generic drugs. CMS names the drug for 1,253 of them, across 36 drugs with 11 or more claims each, at $5,151,728 in total drug cost. In 2023, CMS named 861 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 73 out of 100 for Dr. Andorsky for performance year 2024, reported through an alternative payment model (APM). Dr. Andorsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Andorsky as offering telehealth.

Dmand AI links 19 papers to Dr. Andorsky, published from 2011 to 2024. 2019 was the busiest year, with 3. The most frequent topics are Anxiety, Acceptance and Commitment Therapy and Advance Care Planning. Dr. Andorsky has published most often in Br J Haematol. Dr. Andorsky's most frequent co-authors are Jean S. Kutner, MD, John Matthew Timmerman, MD and Leonard M. Klein.

Dmand AI links Dr. Andorsky to 9 clinical trials, 5 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Lymphoma, Follicular, Lymphoma, Mantle-Cell and Gastrointestinal Stromal Tumors. Loxo Oncology, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Andorsky that name 2 trials.

CMS Open Payments shows 62 general payments to Dr. Andorsky from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 98% of the total. Celgene Corporation paid the most, $11,731. It also lists 42 research payments totaling $456,497 from 2016 to 2025, naming 2 clinical trials.

Dr. Andorsky graduated from Harvard Medical School in 2002.